Related references
Note: Only part of the references are listed.CYP2C19*17 affects R-warfarin plasma clearance and warfarin INR/dose ratio in patients on stable warfarin maintenance therapy
Ming Chang et al.
EUROPEAN JOURNAL OF CLINICAL PHARMACOLOGY (2015)
Prevalence and significance of CYP2C19*2 and CYP2C19*17 alleles in a New Zealand acute coronary syndrome population
P. D. Larsen et al.
INTERNAL MEDICINE JOURNAL (2015)
The Hawaii clopidogrel lawsuit: the possible effect on clinical laboratory testing
Alan H. B. Wu et al.
PERSONALIZED MEDICINE (2015)
A combined high CYP2D6-CYP2C19 metabolic capacity is associated with the severity of suicide attempt as measured by objective circumstances
E. Penas-Lledo et al.
PHARMACOGENOMICS JOURNAL (2015)
Inactive alleles of cytochrome P450 2C19 may be positively selected in human evolution
Ramatoulie E. Janha et al.
BMC EVOLUTIONARY BIOLOGY (2014)
Clinical Pharmacogenetics Implementation Consortium Guidelines for Cytochrome P450 2D6 Genotype and Codeine Therapy: 2014 Update
K. R. Crews et al.
CLINICAL PHARMACOLOGY & THERAPEUTICS (2014)
Frequency distribution of high risk alleles of CYP2C19, CYP2E1, CYP3A4 genes in Haryana population
Sachin Gulati et al.
ENVIRONMENTAL TOXICOLOGY AND PHARMACOLOGY (2014)
Interethnic variability of CYP2D6 alleles and of predicted and measured metabolic phenotypes across world populations
Adrian LLerena et al.
EXPERT OPINION ON DRUG METABOLISM & TOXICOLOGY (2014)
Genetic polymorphisms of CYP2C8, CYP2C9 and CYP2C19 in Ecuadorian Mestizo and Spaniard populations: a comparative study
Jorge Vicente et al.
MOLECULAR BIOLOGY REPORTS (2014)
Distribution of ABCB1, CYP3A5, CYP2C19, and P2RY12 gene polymorphisms in a Mexican Mestizos population
Gilberto Vargas-Alarcon et al.
MOLECULAR BIOLOGY REPORTS (2014)
Characterization of CYP1A2, CYP2C19, CYP3A4 and CYP3A5 polymorphisms in South Brazilians
Fabiana B. Kohlrausch et al.
MOLECULAR BIOLOGY REPORTS (2014)
Decreased hippocampal volume and increased anxiety in a transgenic mouse model expressing the human CYP2C19 gene
A. Persson et al.
MOLECULAR PSYCHIATRY (2014)
Evaluation of the relationship between polymorphisms in CYP2C19 and the pharmacokinetics of omeprazole, pantoprazole and rabeprazole
Manuel Roman et al.
PHARMACOGENOMICS (2014)
A rapid and simple LC-MS/MS method for the simultaneous evaluation of CYP1A2, CYP2C9, CYP2C19, CYP2D6 and CYP3A4 hydroxylation capacity
Fernando de Andres et al.
BIOANALYSIS (2014)
Hydroxylation index of omeprazole in relation to CYP2C19 polymorphism and sex in a healthy Iranian population
Maryam Payan et al.
DARU-JOURNAL OF PHARMACEUTICAL SCIENCES (2014)
Distribution of CYP2C19☆2 and CYP2C19☆3 polymorphisms in Venezuelan populations with different admixture
Dinorah Castro de Guerra et al.
ANNALS OF HUMAN BIOLOGY (2013)
CYP2C19 Genetic Polymorphism in Saudi Arabians
Fahad I. Al-Jenoobi et al.
BASIC & CLINICAL PHARMACOLOGY & TOXICOLOGY (2013)
Introduction of the AmpliChip CYP450 Test to a South African cohort: a platform comparative prospective cohort study
Tyren M. Dodgen et al.
BMC MEDICAL GENETICS (2013)
Newly identified synergy between clopidogrel and calcium-channel blockers for blood pressure regulation possibly involves CYP2C19 rs4244285
Maria G. Stathopoulou et al.
INTERNATIONAL JOURNAL OF CARDIOLOGY (2013)
Genotype-Phenotype Analysis of CYP2C19 in Healthy Saudi Individuals and its Potential Clinical Implication in Drug Therapy
Leena H. Saeed et al.
INTERNATIONAL JOURNAL OF MEDICAL SCIENCES (2013)
High prevalence of CYP2C19*2 allele in Roma samples: study on Roma and Hungarian population samples with review of the literature
Csilla Sipeky et al.
MOLECULAR BIOLOGY REPORTS (2013)
A Systematically Combined Genotype and Functional Combination Analysis of CYP2E1, CYP2D6, CYP2C9, CYP2C19 in Different Geographic Areas of Mainland China - A Basis for Personalized Therapy
Zhenqiang Wu et al.
PLOS ONE (2013)
Neurological toxicity after phenytoin infusion in a pediatric patient with epilepsy: influence of CYP2C9, CYP2C19 and ABCB1 genetic polymorphisms
P. Dorado et al.
PHARMACOGENOMICS JOURNAL (2013)
Pharmacogenomics of drug-metabolizing enzymes: a recent update on clinical implications and endogenous effects
S. C. Sim et al.
PHARMACOGENOMICS JOURNAL (2013)
Distribution of CYP2C Polymorphisms in an Amerindian Population of Brazil
Daniela D. Vargens et al.
BASIC & CLINICAL PHARMACOLOGY & TOXICOLOGY (2012)
Population Differences in Major Functional Polymorphisms of Pharmacokinetics/pharmacodynamics-related Genes in Eastern Asians and Europeans: Implications in the Clinical Trials for Novel Drug Development
Kouichi Kurose et al.
DRUG METABOLISM AND PHARMACOKINETICS (2012)
Allele and Genotype Frequencies of CYP3A4, CYP2C19, and CYP2D6 in Han, Uighur, Hui, and Mongolian Chinese Populations
Liang Jin Zuo et al.
GENETIC TESTING AND MOLECULAR BIOMARKERS (2012)
Distribution of CYP2D6 and CYP2C19 Polymorphisms Associated with Poor Metabolizer Phenotype in Five Amerindian Groups and Western Mestizos from Mexico
Joel Salazar-Flores et al.
GENETIC TESTING AND MOLECULAR BIOMARKERS (2012)
Distribution of CYP2C19*17 allele and genotypes in an Indian population
D. Anichavezhi et al.
JOURNAL OF CLINICAL PHARMACY AND THERAPEUTICS (2012)
Differences in genotype and allele frequency distributions of polymorphic drug metabolizing enzymes CYP2C19 and CYP2D6 in mainland Chinese Mongolian, Hui and Han populations
S. -J. Yin et al.
JOURNAL OF CLINICAL PHARMACY AND THERAPEUTICS (2012)
ALLELE AND GENOTYPE FREQUENCIES OF CYP2B6 AND CYP2C19 POLYMORPHISMS IN EGYPTIAN AGRICULTURAL WORKERS
Corie A. Ellison et al.
JOURNAL OF TOXICOLOGY AND ENVIRONMENTAL HEALTH-PART A-CURRENT ISSUES (2012)
Genetic polymorphism of CYP2C19 in a Jordanian population: influence of allele frequencies of CYP2C19*1 and CYP2C19*2 on the pharmacokinetic profile of lansoprazole
Imad Zalloum et al.
MOLECULAR BIOLOGY REPORTS (2012)
Allele and genotype frequencies of the polymorphic cytochrome P450 genes (CYP1A1, CYP3A4, CYP3A5, CYP2C9 and CYP2C19) in the Jordanian population
Al-Motassem Yousef et al.
MOLECULAR BIOLOGY REPORTS (2012)
Genetic polymorphisms and novel allelic variants of CYP2C19 in the Chinese Han population
Li-Ming Hu et al.
PHARMACOGENOMICS (2012)
Global pharmacogenomics: Impact of population diversity on the distribution of polymorphisms in the CYP2C cluster among Brazilians
G. Suarez-Kurtz et al.
PHARMACOGENOMICS JOURNAL (2012)
The great human expansion
Brenna M. Henn et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2012)
Frequencies of 23 Functionally Significant Variant Alleles Related with Metabolism of Antineoplastic Drugs in the Chilean Population: Comparison with Caucasian and Asian Populations
Ángela Roco et al.
Frontiers in Genetics (2012)
CYP2C19 and ABCB1 gene polymorphisms are differently distributed according to ethnicity in the Brazilian general population
Paulo C. J. L. Santos et al.
BMC MEDICAL GENETICS (2011)
Pilot study for the characterization of pharmacogenetically relevant CYP2D6, CYP2C19 and ABCB1 gene polymorphisms in the Hungarian population
Orsolya Rideg et al.
CELL BIOCHEMISTRY AND FUNCTION (2011)
Analysis of 50 SNPs in CYP2D6, CYP2C19, CYP2C9, CYP3A4 and CYP1A2 by MALDI-TOF mass spectrometry in Chinese Han population
Yan Shi et al.
FORENSIC SCIENCE INTERNATIONAL (2011)
Prevalence of CYP2C19 polymorphisms in the Lebanese population
Isabelle Djaffar Jureidini et al.
MOLECULAR BIOLOGY REPORTS (2011)
Genetic variants in CYP (-1A2,-2C9,-2C19,-3A4 and-3A5), VKORC1 and ABCB1 genes in a black South African population: a window into diversity
Collet Dandara et al.
PHARMACOGENOMICS (2011)
Impact of CYP2C19 variant genotypes on clinical efficacy of antiplatelet treatment with clopidogrel: systematic review and meta-analysis
Tim Bauer et al.
BMJ-BRITISH MEDICAL JOURNAL (2011)
CYP2C19 activity comparison between Swedes and Koreans: effect of genotype, sex, oral contraceptive use, and smoking
Margareta Ramsjo et al.
EUROPEAN JOURNAL OF CLINICAL PHARMACOLOGY (2010)
Linkage disequilibrium between the CYP2C19*17 allele and wildtype CYP2C8 and CYP2C9 alleles: identification of CYP2C haplotypes in healthy Nordic populations
Rasmus S. Pedersen et al.
EUROPEAN JOURNAL OF CLINICAL PHARMACOLOGY (2010)
Microarray-Based Detection of CYP1A1, CYP2C9, CYP2C19, CYP2D6, GSTT1, GSTM1, MTHFR, MTRR, NQO1, NAT2, HLA-DQA1, and AB0 Allele Frequencies in Native Russians
Olga Gra et al.
GENETIC TESTING AND MOLECULAR BIOMARKERS (2010)
Genetic polymorphisms of cytochrome P450 enzymes 2C9 and 2C19 in a healthy Mongolian population in China
Z. F. Yang et al.
GENETICS AND MOLECULAR RESEARCH (2010)
Assessment of CYP2C19 genetic polymorphisms in a korean population using a simultaneous multiplex pyrosequencing method to simultaneously detect the CYP2C19*2, CYP2C19*3, and CYP2C19*17 alleles
K. -A. Kim et al.
JOURNAL OF CLINICAL PHARMACY AND THERAPEUTICS (2010)
Characterization of the genetic profile of CYP2C19 in two South African populations
Britt I. Drogemoeller et al.
PHARMACOGENOMICS (2010)
Characterisation of CYP2C8, CYP2C9 and CYP2C19 polymorphisms in a Ghanaian population
William Kudzi et al.
BMC MEDICAL GENETICS (2009)
Identification of New CYP2C19 Variants Exhibiting Decreased Enzyme Activity in the Metabolism of S-Mephenytoin and Omeprazole
Su-Jun Lee et al.
DRUG METABOLISM AND DISPOSITION (2009)
Genetic Variations and Haplotypes of the 5 ' Regulatory Region of CYP2C19 in South Indian Population
Chakradhara Rao Uppugunduri Satyanarayana et al.
DRUG METABOLISM AND PHARMACOKINETICS (2009)
Cytochrome P450 2C19 genetic polymorphisms in Ugandans
Jun Miura et al.
EUROPEAN JOURNAL OF CLINICAL PHARMACOLOGY (2009)
Pharmacogenomics of CYP2A6, CYP2B6, CYP2C19, CYP2D6, CYP3A4, CYP3A5 and MDR1 in Vietnam
M. I. Veiga et al.
EUROPEAN JOURNAL OF CLINICAL PHARMACOLOGY (2009)
CYP2C19 haplotypes in Koreans as a marker of enzyme activity evaluated with omeprazole
S. K. Jin et al.
JOURNAL OF CLINICAL PHARMACY AND THERAPEUTICS (2009)
Pharmacogenetic variation at CYP2C9, CYP2C19, and CYP2D6 at global and microgeographic scales
Johanna Sistonen et al.
PHARMACOGENETICS AND GENOMICS (2009)
Genetic polymorphism, linkage disequilibrium, haplotype structure and novel allele analysis of CYP2C19 and CYP2D6 in Han Chinese
Q. Zhou et al.
PHARMACOGENOMICS JOURNAL (2009)
Limited frequency of the CYP2C19*17 allele and its minor role in a Japanese population
Katsuyoshi Sugimoto et al.
BRITISH JOURNAL OF CLINICAL PHARMACOLOGY (2008)
Pharmacokinetics/genotype associations for major cytochrome P450 enzymes in native and first- and third-generation Japanese populations: Comparison with Korean, Chinese, and Caucasian populations
S. P. Myrand et al.
CLINICAL PHARMACOLOGY & THERAPEUTICS (2008)
Global pharmacogenetics: genetic substructure of Eurasian populations and its effect on variants of drug-metabolizing enzymes
Oksana Makeeva et al.
PHARMACOGENOMICS (2008)
Genetic polymorphism analysis of CYP2C19 in Chinese Han populations from different geographic areas of mainland China
Lingling Chen et al.
PHARMACOGENOMICS (2008)
Impact of the ultrarapid CYP2C19*17 allele on serum concentration of escitalopram in psychiatric patients
I. Rudberg et al.
CLINICAL PHARMACOLOGY & THERAPEUTICS (2008)
Genetic polymorphism of CYP2C19 in Maharashtrian population
Yogita Ghodke et al.
EUROPEAN JOURNAL OF EPIDEMIOLOGY (2007)
Comparisons of CYP2C19 genetic polymorphisms between Korean and Vietnamese populations
Sang Seop Lee et al.
THERAPEUTIC DRUG MONITORING (2007)
Genetic polymorphisms of drug-metabolizing enzymes CYP2D6, CYP2C9, CYP2C19 and CYP3A5 in the Greek population
Kostas Arvanitidis et al.
FUNDAMENTAL & CLINICAL PHARMACOLOGY (2007)
Genetic polymorphism of cytochrome P450s and P-glycoprotein in the Finnish population
Johanna Hilli et al.
FUNDAMENTAL & CLINICAL PHARMACOLOGY (2007)
CYP2C9, CYP2C19 and CYP2D6 allele frequencies in the Ashkenazi Jewish population
StuartA Scott et al.
PHARMACOGENOMICS (2007)
Pharmacogenetically relevant polymorphisms in Portugal
E. Oliveira et al.
PHARMACOGENOMICS (2007)
Genetic polymorphisms of cytochrome P450 enzymes 2C9 and 2C19 in a healthy Iranian population
Negin Zand et al.
CLINICAL AND EXPERIMENTAL PHARMACOLOGY AND PHYSIOLOGY (2007)
Genetic polymorphism of cytochrome P4502C19 in Mexican Americans: A cross-ethnic comparative study
Huai-Rong Luo et al.
CLINICAL PHARMACOLOGY & THERAPEUTICS (2006)
Multiple regression analysis of pharmaeogenetic variability of carvedilol disposition in 54 healthy Japanese volunteers
M Honda et al.
BIOLOGICAL & PHARMACEUTICAL BULLETIN (2006)
CYP2C19 genetic polymorphism in Thai, Burmese and Karen populations
Wichittra Tassaneeyakul et al.
DRUG METABOLISM AND PHARMACOKINETICS (2006)
Genetic polymorphism of CYP2C9 and CYP2C19 in a Bolivian population:: an investigative and comparative study
HV Bravo-Villalta et al.
EUROPEAN JOURNAL OF CLINICAL PHARMACOLOGY (2005)
The effect of the CYP2C19 genotype on the hydroxylation index of omeprazole in South Indians
J Rosemary et al.
EUROPEAN JOURNAL OF CLINICAL PHARMACOLOGY (2005)
High-throughput detection of multiple genetic polymorphisms influencing drug metabolism with mismatch primers in allele-specific polymerase chain reaction
A Ishiguro et al.
ANALYTICAL BIOCHEMISTRY (2005)
Amitriptyline or not, that is the question:: Pharmacogenetic testing of CYP2D6 and CYP219 identifies patients with low or high risk for side effects in amitriptyline therapy
W Steimer et al.
CLINICAL CHEMISTRY (2005)
CYP2C9 and CYP2C19 genetic polymorphisms:: frequencies in the south Indian population
R Jose et al.
FUNDAMENTAL & CLINICAL PHARMACOLOGY (2005)
Genetic polymorphism of cytochrome P4502C19 in healthy Malaysian subjects
YS Yang et al.
BRITISH JOURNAL OF CLINICAL PHARMACOLOGY (2004)
Allele and genotype frequencies of CYP2C9, CYP2C19 and CYP2D6 in an Italian population
MG Scordo et al.
PHARMACOLOGICAL RESEARCH (2004)
Reliability of the omeprazole hydroxylation index for CYP2C19 phenotyping: possible effect of age, liver disease and length of therapy
Miyuki Kimura et al.
BRITISH JOURNAL OF CLINICAL PHARMACOLOGY (2003)
Genetic polymorphisms of CYP2C9 and CYP2C19 in the Beninese and Belgian populations
AC Allabi et al.
BRITISH JOURNAL OF CLINICAL PHARMACOLOGY (2003)
Allele and genotype frequency of CYP2C19 in a Tamilian population
C Adithan et al.
BRITISH JOURNAL OF CLINICAL PHARMACOLOGY (2003)
Polymorphisms of drug-metabolizing enzymes CYP2C9, CYP2C19, CYP2D6, CYP1A1, NAT2 and of P-glycoprotein in a Russian population
EA Gaikovitch et al.
EUROPEAN JOURNAL OF CLINICAL PHARMACOLOGY (2003)
Association between blood carisoprodol:: meprobamate concentration ratios and CYP2C19 genotype in carisoprodol-drugged drivers:: decreased metabolic capacity in heterozygous CYP2C19*1/CYP2C19*2 subjects?
JG Bramness et al.
PHARMACOGENETICS (2003)
CYP2C19- and CYP3A4-dependent omeprazole metabolism in West Mexicans
HM Gonzalez et al.
JOURNAL OF CLINICAL PHARMACOLOGY (2003)
Polymorphic oxidative metabolism of proguanil in a Nigerian population
OO Bolaji et al.
EUROPEAN JOURNAL OF CLINICAL PHARMACOLOGY (2002)
Evidence for environmental influence on CYP2D6-catalysed debrisoquine hydroxylation as demonstrated by phenotyping and genotyping of Ethiopians living in Ethiopia or in Sweden
E Aklillu et al.
PHARMACOGENETICS (2002)
Allele and genotype frequencies of polymorphic cytochromes P450 (CYP2C9, CYP2C19, CYP2E1) and dihydropyrimidine dehydrogenase (DPYD) in the Egyptian population
SI Hamdy et al.
BRITISH JOURNAL OF CLINICAL PHARMACOLOGY (2002)
Analysis of the CYP2C19 polymorphism in a North-eastern Thai population
W Tassaneeyakul et al.
PHARMACOGENETICS (2002)
CYP2C19 genotype and S-mephenytoin 4′-hydroxylation phenotype in a Chinese Dai population
N He et al.
EUROPEAN JOURNAL OF CLINICAL PHARMACOLOGY (2002)
Genetic polymorphism of CYP2D6 and CYP2C19 in East- and Southern African populations including psychiatric patients
C Dandara et al.
EUROPEAN JOURNAL OF CLINICAL PHARMACOLOGY (2001)
Allele and genotype frequencies of polymorphic cytochromes P4502D6, 2C19 and 2E1 in Aborigines from Western Australia
EU Griese et al.
PHARMACOGENETICS (2001)
Molecular basis of ethnic differences in drug disposition and response
HG Xie et al.
ANNUAL REVIEW OF PHARMACOLOGY AND TOXICOLOGY (2001)
Share Paper
